Merck & Co Inc MRK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Citi tells investors it's time to sell Moderna after 600%-plus stock gains
-
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics — Update
-
Merck in License Pact Worth Up to $2.13 Billion With SciBrunch Therapeutics
-
Merck, Daiichi Sankyo Withdraw Application for Accelerated Approval of Lung Cancer Treatment
-
Merck, Eisai Get FDA OK of Welireg/Lenvima Combo in Kidney Cancer
-
Merck Phase 2b/3 Trial for Remigromig Meets Primary Endpoint
-
Moderna will reveal the data for its mRNA cancer vaccine next month. Here's why it matters.
-
Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped
Trading Information
- Previous Close Price
- —
- Day Range
- CHF 95.30–95.30
- 52-Week Range
- CHF 95.30–95.30
- Bid/Ask
- CHF 118.10 / CHF 119.66
- Shares Outstanding
- 2.47B
- Market Cap
- $235.37B
- Volume/Avg
- 50 / 50
Key Statistics
- Price/Earnings (Normalized)
- 47.55
- Price/Sales
- 5.69
- Dividend Yield (Trailing)
- 1.73%
- Dividend Yield (Forward)
- 2.36%
- Dividend Payment Schedule
- Apr, Jul
- Total Yield
- 2.86%
Company Profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 75,000
- Website
- https://www.merck.com
Competitors
Valuation
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 47.55 | 36.51 | 9.22 |
Price/Book Value | 8.83 | 30.26 | 1.88 |
Price/Sales | 5.69 | 12.94 | 2.53 |
Price/Cash Flow | 17.09 | 31.35 | 10.46 |
Price/Earnings
MRK
LLY
PFE
Financial Strength
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Quick Ratio | 0.71 | 0.68 | 0.85 |
Current Ratio | 1.32 | 1.35 | 1.27 |
Interest Coverage | 4.28 | — | 2.36 |
Quick Ratio
MRK
LLY
PFE
Profitability
|
Metric
|
MRK
|
LLY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 6.27% | 24.05% | 8.46% |
Return on Equity (Normalized) | 16.68% | 105.62% | 19.70% |
Return on Invested Capital (Normalized) | 9.82% | 39.55% | 12.66% |
Return on Assets
MRK
LLY
PFE
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|TM<f<&X? | LOCK|!rd | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|r??xsg> | LOCK|G< | $617B | |||
| AbbVie Inc
ABBV
| LOCK|QHPPgr< | LOCK|sN | $464B | |||
| Merck & Co Inc
MRK
| LOCK|#<@?<h | LOCK|FhF | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|xM^$PG& | LOCK|mV | $333B | |||
| Novartis AG ADR
NVS
| LOCK|#!>L!p> | LOCK|&B | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|>H>%Lk<^ | LOCK|c? | $243B | |||
| Amgen Inc
AMGN
| LOCK|D!>&z$z | LOCK|#>X | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|@!CTH% | LOCK|?! | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|&R@Q%%l | LOCK|k> | $165B |
United States